{"id":50077,"date":"2022-10-26T09:01:42","date_gmt":"2022-10-26T07:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-presents-new-mri-and-updated-open-label-extension-data-from-phase-1-study-of-ata188-in-progressive-multiple-sclerosis-at-ectrims-2022\/"},"modified":"2022-10-26T09:01:42","modified_gmt":"2022-10-26T07:01:42","slug":"atara-biotherapeutics-presents-new-mri-and-updated-open-label-extension-data-from-phase-1-study-of-ata188-in-progressive-multiple-sclerosis-at-ectrims-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-presents-new-mri-and-updated-open-label-extension-data-from-phase-1-study-of-ata188-in-progressive-multiple-sclerosis-at-ectrims-2022\/","title":{"rendered":"Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022"},"content":{"rendered":"
\n

\nSustained Improvement Observed in ATA188 Treated Patients Achieving Confirmed Disability Improvement (CDI) in Open Label Extension (OLE) with up to 46 Months Follow up<\/i>\n<\/p>\n

\nPatients T<\/i>reated with ATA188 that Achieved CDI Demonstrate Significantly Less Brain Atrophy in Longitudinal Analysis Through 42 Months<\/i>\n<\/p>\n

\nAll Patients in the OLE with Stable Disease Remained Stable for up to 48 Months<\/i>\n<\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc.<\/a> (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced new magnetic resonance imaging (MRI) biomarker and open-label extension (OLE) clinical data from the study of ATA188, an investigational Epstein-Barr virus (EBV)-targeted T-cell immunotherapy, in progressive multiple sclerosis (MS). These findings will be presented as a late-breaking ePoster at the 38th<\/sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) taking place October 26-28, 2022, in Amsterdam, the Netherlands.\n<\/p>\n

<\/a><\/p>\n

\nDuring the initial 12 months, or in the OLE, seven of the 24 patients achieved confirmed disability improvement (CDI), by expanded disability status scale (EDSS), defined as EDSS improvement versus baseline that is confirmed at two consecutive timepoints; 13 had stable EDSS and four had confirmed disability progression (CDP). Additionally, nine met sustained disability improvement (SDI) criteria, a composite scale combining confirmed improvement in either the EDSS score or timed 25-foot walk test in the initial 12-month period (n=7) or in the OLE (n=2). These data demonstrate that ATA188 continues to be well-tolerated, and safety is consistent with previous reports with no Grade >3 events, dose limiting toxicities, cytokine release syndrome, or graft versus host disease.\n<\/p>\n

\n\u201cNew biomarker imaging data presented at ECTRIMS suggest brain structural changes and potential remyelination may underlie clinical disability improvements observed with ATA188 treatment,\u201d said AJ Joshi, MD, Chief Medical Officer at Atara. \u201cWe are pleased to see a majority of patients experiencing either long term durability of CDI based on EDSS improvement or long-term stability in EDSS, which would also represent a transformational profile relative to the expected natural course of the disease.\u201d\n<\/p>\n

\nAs of September 2022, patients achieving CDI continuing in the OLE have been followed for up to 46.5 months. Five of five patients continued to maintain CDI for a median of 27.5 (range, 23.8\u201336.7) months. Eight of eight participants with stable EDSS remaining in the OLE continued to have a stable EDSS for a median of 41.2 (36.3\u201348.5) months.\n<\/p>\n

\nIn the study, changes in whole-brain and regional brain volumes were assessed longitudinally utilizing T1-weighted and FLAIR MRI images. Specific measures of atrophy included percentage brain volume change (PBVC), percentage ventricular volume change (PVVC, where increasing ventricular volume is indicative of increased atrophy in general, and specifically subcortical atrophy), and thalamic volume change (TVC) assessed on T1-weighted MRI. Myelin density was assessed longitudinally through nMTR images in T2 unenhancing lesions and in the normal-appearing brain tissue.\n<\/p>\n

\nDuring the initial 12 months:\n<\/p>\n